Detalhe da pesquisa
1.
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
N Engl J Med;
390(20): 1849-1861, 2024 May 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38739079
2.
Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
Circulation;
149(7): 498-509, 2024 02 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37961906
3.
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
Circulation;
147(11): 850-863, 2023 03 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36335531
4.
Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry.
Circulation;
148(5): 394-404, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37226762
5.
Effectiveness of the Family Heart Talk Communication Tool in Improving Family Member Screening for Dilated Cardiomyopathy: Results of a Randomized Trial.
Circulation;
147(17): 1281-1290, 2023 04 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36938756
6.
Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study.
Circulation;
148(11): 872-881, 2023 09 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37641966
7.
Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines - Heart Failure Registry.
J Card Fail;
30(2): 319-328, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37757995
8.
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
J Card Fail;
2024 Mar 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38493832
9.
Frequency, Penetrance, and Variable Expressivity of Dilated Cardiomyopathy-Associated Putative Pathogenic Gene Variants in UK Biobank Participants.
Circulation;
146(2): 110-124, 2022 07 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35708014
10.
Quantitative metrics of the LV trabeculated layer by cardiac CT and cardiac MRI in patients with suspected noncompaction cardiomyopathy.
Eur Radiol;
2023 Dec 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38114847
11.
Genetic Architecture of Dilated Cardiomyopathy in Individuals of African and European Ancestry.
JAMA;
330(5): 432-441, 2023 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37526719
12.
Inflammation and Immune Response in Arrhythmogenic Cardiomyopathy: State-of-the-Art Review.
Circulation;
144(20): 1646-1655, 2021 11 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34780255
13.
TTR variants in patients with dilated cardiomyopathy: An investigation of the DCM Precision Medicine Study.
Genet Med;
24(7): 1495-1502, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35438637
14.
Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure.
J Card Fail;
28(4): 554-563, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34785402
15.
Sex Differences in Left Ventricular Assist Device-related Emergency Department Encounters in the United States.
J Card Fail;
28(9): 1445-1455, 2022 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35644307
16.
MYH7 variants cause complex congenital heart disease.
Am J Med Genet A;
188(9): 2772-2776, 2022 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35491958
17.
Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy.
Eur Heart J;
42(38): 3932-3944, 2021 10 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34491319
18.
Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy.
JAMA;
327(5): 454-463, 2022 02 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35103767
19.
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet;
396(10253): 759-769, 2020 09 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32871100
20.
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
Am Heart J;
239: 80-89, 2021 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34038706